Don’t see what you’re looking for? Use the search box on MDA’s Quest magazine.
With funding from MDA, the ALS Therapy Development Institute is testing whether the immune system modulator CTLA4-FC slows disease progression in ALS mice
Posted on Thursday, December 29, 2011 - 06:00, By: Margaret Wahl
The Muscular Dystrophy Association has awarded a $278,850 grant to the ALS Therapy Development Institute (ALS TDI) in Cambridge, Mass., to support testing of a mouse version of a compound called CTLA4-FC in the SOD1 research mouse model of amyotrophic lateral sclerosis (ALS).
Posted on Friday, June 1, 2007 - 09:16, By: Other
Sam and Jo-Ann Goldstein of St. Louis have learned a lot about living with ALS since he received his diagnosis in 2005. In this fourth installment of an intermittent series about one person’s ALS journey, Sam shares how his ALS caused a sudden respiratory crisis, leading to large and difficult...